Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinoma

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 42

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

838

HTML

7880

Figures (1-8)

465

Tables (1-3)

210

Sum=9393

Nov 14, 2012 (publication date) through Nov 4, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Gastroenterol. Nov 14, 2012; 18(42): 6005-6017
Published online Nov 14, 2012. doi: 10.3748/wjg.v18.i42.6005

Table 3 Subanalysis data of the SHARP study

		Advanced HCC with vascular invasion and/or extrahepatic spread	Advanced HCC without vascular invasion and/or extrahepatic spread
Hazard ratio		0.77 (95% CI: 0.60-0.99)	0.52 (95% CI: 0.32-0.85)
Median OS (MST) (mo)	Sorafenib	8.9 (n = 209) (95% CI: 7.6-10.3)	14.5 (n = 90) (95% CI: 14.0-N/E)
Median OS (MST) (mo)	Placebo	6.7 (n = 212) (95% CI: 5.2-8.0)	10.2 (n = 91) (95% CI: 8.6-15.5)

HCC: Hepatocellular carcinoma; OS: Overall survival; MST: Median survival time.

Citation: Kudo M. Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinoma. World J Gastroenterol 2012; 18(42): 6005-6017
URL: https://www.wjgnet.com/1007-9327/full/v18/i42/6005.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i42.6005